During the American College of Rheumatology 2018 annual meeting, which will be held from October 19-24 in Chicago, Illinois, a variety of researchers will present on real-world data concerning biosimilar infliximab CT-P13.
During the American College of Rheumatology (ACR) 2018 annual meeting, which will be held from October 19-24 in Chicago, Illinois, a variety of researchers will present on real-world data concerning biosimilar infliximab CT-P13.
RISE Registry Data Show Only Modest Adoption of CT-P13
Researchers studying data from the ACR Rheumatology Informatics System for Effectiveness (RISE) registry will report their findings that, in the first 1.5 years of biosimilar infliximab’s availability in the United States, there were only modest gains for biosimilar CT-P13 in clinical practice.1
The study used electronic medical record data from the RISE registry covering the time period from September 2016 to March 2018, and found that 857 patients at 73 practices (representative of approximately 30% of all practices participating in the registry) received a biosimilar infliximab therapy. All of these patients received CT-P13, sold in the United States as Inflectra—none were prescribed the other US-approved biosimilar infliximab, infliximab-abda, sold as Renflexis.
The highest numbers of prescriptions for the biosimilar were in California (n = 137), followed by West Virginia (n = 101), and Texas (n = 96). Among patients given the biosimilar, 63.4% were switched from the reference product, while the rest were naïve to infliximab treatment.
According to the authors, these data demonstrate only “modest uptake in biosimilar usage, all for Inflectra.”
CT-P13 Is Safe and Effective in French Patients, Whether Infliximab-Naïve or Switched
Researchers from France will report on CT-P13 use data gathered from the REFLECT trial, a multicenter, prospective, observational study.2
A total of 339 patients with rheumatic diseases were included in the registry in December 2017, 83 of whom had rheumatoid arthritis (RA), 213 of whom had axial spondyloarthritis (axSpA), and 43 of whom had psoriatic arthritis (PsA).
Of this group, 41.9% of those with RA, 49.7% of those with axSpA, and 42.9% of those with PsA switched from the reference infliximab to CT-P13.
At the time of the first infusion of the biosimilar, the median disease activity scores for patients with RA in a count of 28 joints were 4.9 and 2.5 for infliximab-naïve and switched patients, respectively. Among those with PsA, these scores were 3.5 and 2.2 for the naïve and switched patients, respectively. Among those with axSpA, the median Bath ankylosing spondylitis disease activity index scores were 5.5 and 2.1 for naïve and switched patients, respectively.
At 6 months, 48.5% of those with RA and 37.7% of those with axSpA had achieved remission. (Analysis of those with PsA will not be reported by the investigators due to the small number of patients who have had 6-month follow-ups to date.)
The median disease activity scores decreased from the first administration of CT-P13 to 6-month follow-up in the infliximab-naïve patients, and remained stable in those who switched, write the authors.
1. Bansback N, Curtis JR, Huang J, et al. Patterns of biosimilar use in the Rheumatology Informatics System for Effectiveness (RISE) registry. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 1891. https://acrabstracts.org/abstract/patterns-of-biosimilar-use-in-the-rheumatology-informatics-system-for-effectiveness-rise-registry/.
2. Marotte H, Mammar N, Fautrel B. Biosimilar infliximab treated-patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in France: characteristics and clinical outcomes. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 2154. https://acrabstracts.org/abstract/biosimilar-infliximab-treated-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-in-france-characteristics-and-clinical-outcomes/.